Premium
Androgen Control in Prostate Cancer
Author(s) -
Pelekanou Vasiliki,
Castanas Elias
Publication year - 2016
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.25572
Subject(s) - prostate cancer , medicine , context (archaeology) , prostatectomy , management of prostate cancer , disease , cancer , oncology , prostate , androgen receptor , bioinformatics , biology , paleontology
Research on prostate cancer has extensively advanced in the past decade, through an improved understanding for its genetic basis and risk‐stratification. Molecular classification of prostate cancer into distinct subtypes and the recognition of new histologic entities promise the development of tailored‐made management strategies of patients. Nowadays, various alternatives are available for clinical management of localized disease ranging from observation alone through radical prostatectomy. In patients with castration‐resistant prostate cancer, the approval of new drugs for the management of metastatic disease has offered promising results improving the survival of these patients. In this context, androgen receptors (AR) remain at the epicenter of prostate cancer research holding a prominent role in the biology and therapeutic regimens of prostate cancer. As many of castration‐resistant tumors retain hormone‐responsiveness, AR is a clinical relevant, druggable target. However, AR paradoxically remains neglected as a prostate cancer biomarker. The great advancements in prostate cancer preclinical and clinical research, imply further improvement in clinical and translational data, for patient selection and treatment optimization. For a precision medicine‐guided clinical management of prostate cancer, AR evaluation has to be implemented in companion and complementary diagnostics, as discussed here. J. Cell. Biochem. 117: 2224–2234, 2016. © 2016 Wiley Periodicals, Inc.